Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis.
Smith SD, Lopedote P, Samara Y, Mei M, Herrera AF, Winter AM, Hill BT, Shadman M, Ujjani C, Lynch RC, Jacobson CA, Kim AI, Caimi P, Milano F, Gopal AK.
Smith SD, et al.
Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):170-175. doi: 10.1016/j.clml.2020.12.013. Epub 2020 Dec 18.
Clin Lymphoma Myeloma Leuk. 2021.
PMID: 33431309